Search

everythinglearnresearchcommunity

for

Search:↓

L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.

The conversation is about a person's two-year hair regrowth progress using finasteride, minoxidil, ketoconazole, and microneedling. They are comparing their hair from April 21, 2022, to April 13, 2024.

Formula 82M, a minoxidil and retinol liquid, improved hair texture and filled in temples with baby hairs for the user, but its high cost and lack of reviews cause concern. Another user mentioned using a similar product, 82F, which has become less effective and expensive over time.

The user experienced significant hair regrowth and improved hair volume after 4 months of using oral dutasteride (0.5 mg) and minoxidil (2.5 mg) daily, eliminating the need for a second hair transplant. The user is now satisfied with the results and feels more confident.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

Low-level laser therapy (LLLT) is debated for hair regrowth, with some users suggesting it should be combined with treatments like minoxidil and finasteride for effectiveness. Many users express skepticism about LLLT's efficacy and cost, emphasizing the need for the correct wavelength and quality devices.

Ramsko1's experience with a hair loss regimen of oral minoxidil, dutasteride, ketoconazole cream, and dermarolling, which they started after considering taking their own life due to hair loss. Other users replied to offer support and ask questions about specific treatments.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

A user's progress with a hair loss treatment regimen consisting of minoxidil, finasteride, and dermarolling once a week over four months; other users have offered encouragement and advice.

A user's progress in treating their hair loss with finasteride, minoxidil and oral minoxidil, as well as microneedling. Replies to the post have encouraged the user that they are seeing regrowth from the treatments.

A user has been using Minoxidil and dermarolling for 4 months to treat hair loss, with some success. However, others suggest that without adding finasteride to the regimen, the hair regrowth may not last.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The user experienced good hair growth using topical minoxidil 5% and finasteride for 4 months but lost progress after switching to oral minoxidil and finasteride and shaving their head. They have returned to using topical treatments and are seeking advice on similar experiences.

The user experienced hair regrowth using daily oral finasteride and topical minoxidil applied about five times a week, with some existing hair becoming thicker and new growth appearing. They also used dermastamping once a month and are considering adding topical GHK-Cu to their regimen.

The user is happy with the progress in hair density after using a regimen of oral Dutasteride, topical Minoxidil, Tretinoin cream, Ketoconazole shampoo, and an LLLT helmet. They reported no side effects and noted that Dutasteride and Tretinoin were particularly effective.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

The user experienced significant hair shedding but is now seeing regrowth after 4 months on finasteride and 2 months on minoxidil, with no major side effects. They use 1 mg finasteride daily, 2.5 mg minoxidil daily, and derm stamping weekly.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

Low-level laser therapy (LLLT) is discussed as a supplementary treatment for hair loss, with users recommending brands like LaserCap, Ideatherapy, Capillus Pro, and iRestore Pro. Users suggest combining LLLT with treatments like minoxidil and finasteride for better results.

The user experienced significant hair regrowth using 5 mg daily oral minoxidil and ketoconazole shampoo, improving from Norwood 3 to Norwood 2. They recommend starting treatment early, noting reduced shedding and stable results.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

User shares 4-month progress using daily minoxidil, topical finasteride, and microneedling. Results spark debate on effectiveness and authenticity.

The conversation is about a user's four-month progress using finasteride, minoxidil, and weekly dermastamping for hair loss. People occasionally notice improvements in the user's hair.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.